Canadian Sciences Speakers Network

Réseau Canadien de Panélistes Scientifiques


Default Profile Photo

David Brooks

Toronto, Ontario

Position: Senior Scientist and Professor

Organization: Princess Margaret Cancer Center and University of Toronto

Dr. David Brooks is a Senior Scientist in the Tumor Immunotherapy Program at the Princess Margaret Cancer Center (PMCC), and a Professor in the Department of Immunology, Faculty of Medicine, at the University of Toronto. Dr. Brooks’ laboratory is focused on understanding the molecular mechanisms and cellular interactions that regulate immune responses in chronic infections and cancer. His group has shown that these diseases are associated with inflammation that counter-intuitively exacerbates immune dysfunction to promote disease progression. His goal is to use this information to design therapies that broadly restore immunity to fight infections and cancer. Before relocating to Canada, Dr. Brooks was a tenured Associate Professor and led a laboratory at University of California, Los Angeles (UCLA) for seven years. Dr. Brooks did his post-doctoral fellowship with Dr. Michael Oldstone at The Scripps Research Institute in La Jolla, California studying the immune response to chronic virus infection. Dr. Brooks earned his Ph.D. from UCLA under the mentorship of Dr. Jerome Zack, studying HIV latency and therapeutic strategies to reactivate the latent virus. Dr. Brooks earned his B.S. in Molecular and Cellular Biology from the University of Arizona. He was born and raised in Venice, California.

Areas of Expertise:

+ Tumor Immunology
+ Immunotherapy
+ Viral immunology

Language(s):

+ English


My Work

Ask me about:

Understanding the immune response to chronic infections and cancer, with a focus on inflammation, immunosuppression, and therapy.


About Me

Sector: Academia (Post Secondary)

English proficiency: Read, Write, Speak

Title: Dr.

Gender: Male


Recent Publications

Title Year
Lymph node macrophages drive immune tolerance and resistance to cancer therapy by induction of the immune-regulatory cytokine IL-332025
Cross-Cancer Analysis Reveals Distinct Pattern of Immune Modulation during Curative Radiotherapy2024
100 Cross-Cancer Analysis Reveals Distinct Pattern of Immune Modulation During Curative Radiotherapy: Preliminary Findings from the Sciper Study2024
In vivo CRISPR screens identify a dual function of MEN1 in regulating tumor–microenvironment interactions2024
Obesity intensifies sex-specific interferon signaling to selectively worsen central nervous system autoimmunity in females2024
GNAS knockout potentiates HDAC3 inhibition through viral mimicry-related interferon responses in lymphoma2024
Regulation and impact of tumor-specific CD4+ T cells in cancer and immunotherapy2024
IL-2 produced by HBV-specific T cells as a biomarker of viral control and predictor of response to PD-1 therapy across clinical phases of chronic hepatitis B2023
Abstract B005: Molecular, metabolic and functional CD4 T cell paralysis in lymph node impedes tumor control2023
Abstract A004: Immune response to sub-ablative radiation before surgery in pleural mesothelioma – Results from the SMARTER trial2023
Molecular, metabolic, and functional CD4 T cell paralysis in the lymph node impedes tumor control2023
Medullary sinus macrophages limit cancer therapy efficacy by an efferocytosis-induced IL-33/ST2 axis in the tumor-draining lymph node.2023
The transcription factor IRF2 drives interferon-mediated CD8+ T cell exhaustion to restrict anti-tumor immunity2022
Mass cytometry immunostaining protocol for multiplexing clinical samples2022
Pre-encoded responsiveness to type I interferon in the peripheral immune system defines outcome of PD1 blockade therapy2022
Peripheral CD4 T cell resistance to type I interferon defines outcome of PD1 blockade therapy in human cancer2022
Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer2022
Tryptophan-derived microbial metabolites activate the aryl hydrocarbon receptor in tumor-associated macrophages to suppress anti-tumor immunity2022
Dynamic CD4+ T cell heterogeneity defines subset-specific suppression and PD-L1-blockade-driven functional restoration in chronic infection2021
Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity2021
Immune profiling of advanced, recurrent metastatic endometrial cancer using high-dimensional time-of-flight mass cytometry (CyTOF)2021
Prevention of CD8 T Cell Deletion during Chronic Viral Infection2021
Uncovering the underlying immune perturbations that determine long-term severity of chronic virus and Mycobacterium tuberculosis coinfection2021
DNA hypomethylating agents increase activation and cytolytic activity of CD8+ T cells2021
Early innate and adaptive immune perturbations determine long-term severity of chronic virus and Mycobacterium tuberculosis coinfection2021